Please assess the completion status of the following clinical trial:

Trial Title: Comparison of New Anti-HIV Drug Combinations in HIV-Infected Children Who Have Taken Anti-HIV Drugs

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: None
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria~Concurrent Medication:~Allowed:~* IVIG and opportunistic infection prophylaxis will be allowed.~* Erythropoietin (EPO), granulocyte colony-stimulating factor (G-CSF) and granulocyte-macrophage colony- stimulating factor (GM-CSF) will be allowed for the management of hematologic toxicity.~* Treatment with trimethoprim is allowed at the discretion of the principal investigator.~Patients must have:~* Laboratory evidence (at least 2 viral tests) of HIV-1 infection.~* Clinical and immunological stability \[maintained CDC category 1 or 2 immunologic status for past 4 months and no new CDC category (diagnosis within the past year)\].~* Patients must have received continuous antiretroviral therapy for the past 16 weeks (missing no more than 6 weeks of therapy during the previous 16 weeks).~AS PER AMENDMENT 10/20/97: For PRAM-1, Step 2:~* Viral load \>= 10,000 and \< 100,000 copies/ml at week 12, 24, or 36 in children initially assigned to Arm I (ZDV + 3TC) of PRAM-1 and currently on study.~Prior Medication:~Required:~* Patients must have received continuous antiretroviral therapy for the past 16 weeks.~Allowed:~* Patients who have received immunomodulator therapy as part of perinatal clinical trials or in trials for HIV- exposed infants are eligible.~Exclusion Criteria~Co-existing Condition:~Patients with the following symptoms or conditions are excluded:~* Current grade 3/4 clinical or laboratory toxicity and/or current grade 2 or higher amylase/lipase toxicity.~* Active opportunistic infection and/or serious bacterial infection.~* Current diagnosis of malignancy.~Concurrent Medication:~Excluded:~* Current antiretroviral therapy identical to any of the following regimens:~* ZDV + 3TC, d4T + ritonavir and ZDV + 3TC + ritonavir.~* Concurrent therapy with any other anti-HIV-1 therapy, biologic response modifiers (EPO, G-CSF and GM-CSF allowed), human growth hormone and megestrol acetate.~* Use of continuous systemic corticosteroids (\>= 14 days duration) is not allowed.~* Medications that are incompatible with ritonavir.~* Probenecid and daily intravenous pentamidine.~\[AS PER AMENDMENT 10/23/98: The following are excluded in patients receiving indinavir:~* terfenadine, astemizole, cisapride, rifampin, rifabutin, triazolam, ketoconazole, clarithromycin, carbamazepine, phenobarbital, phenytoin, calcium channel blockers, midazolam, and ergot derivatives.\]~Patients with the following prior conditions and symptoms are excluded:~* Documented hypersensitivity to a therapy included in any of the treatment arms.~Prior Medication:~Excluded:~Investigational drug therapy within 2 weeks prior to randomization.~NOTE:~* Co-enrollment in ACTG 219, ACTG 220 and certain ACTG opportunistic infection protocols is allowed.

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete